The positive data marks a critical pivot for the biotechnology firm, whose shares had suffered a 30% decline year-to-date through Monday’s close. In the trial, the drug demonstrated a statistically significant reduction in the risk of composite kidney disease progression, specifically targeting proteinuria—the presence of excess protein in the urine. Beyond its efficacy, the company reported that the treatment maintained a safety profile comparable to a placebo, a vital metric for long-term adoption.

Chief Executive Marshall Fordyce confirmed that the company is preparing a supplemental biologics license application for the U.S. Food and Drug Administration. Vera anticipates filing this request in the fourth quarter, aiming for full regulatory approval by 2027. If successful, Trutakna would provide a new clinical pathway for patients facing the global burden of chronic kidney disease.